Key facts
- Iolyx Therapeutics’s last known valuation is $64.0M (Dec 2025).
- It has raised $45.0M; the latest was Later Stage VC ($15.0M) in Dec 2025.
- Notable investors include Alumni Ventures, Frazier Healthcare Partners, Frazier Lifesciences Acquisition, GC&H Investments.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Iolyx Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Iolyx Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Iolyx Therapeutics
Manufacturer of a clinical-stage company intending to transform the standard of care for ocular disease at the intersection of immunology and ophthalmology. The company's platform offers tailored formulations for precise local delivery of immunological drugs to relevant tissues, targeting ocular inflammation at its source, in the front and back of the eye, enabling clients efficacy, safety, and convenience.
- Sector
- Business Products and Services (B2B)
- HQ
- Burlingame, CA, United States
- Founded
- 2019
- Employees
- 4
- Website
- iolyx.com/
- Ownership
- Privately Held (backing)
Iolyx Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Iolyx Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Iolyx Therapeutics in its N-PORT filings yet. We sweep new filings monthly.